13F reference period
Q2 2026
Security Snapshot
Entrada Therapeutics, Inc. - Common Stock (TRDA) Institutional Ownership
CUSIP: 29384C108
13F Institutional Holders and Ownership History from Q4 2021 to Q3 2026
Institutions Reporting
127
Shares (Excl. Options)
29.05M
Full value: 29,052,007 · shares · 30 Jun 2026Price
$7.36
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- TRDA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 29,052,007
- Total 13F value
- $213,997,599
- Portfolio coverage rank
- 0%
- Share change
- +3,691,964
- Value change
- +$23,782,839
- Number of holders
- 127
- Shares outstanding
- 39,243,586
- SEC-reported price per share
- $5.38
- Insider filing price
- $5.38
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- TRDA - Entrada Therapeutics, Inc. - Common Stock is tracked under CUSIP 29384C108.
- 127 institutions reported positions in Q2 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 118 to 127 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$321.44M
Full value: $321,439,067 · USD · 31 Mar 2026.$214M
Full value: $213,997,599 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 127 institutions filings for Q2 2026.
Security key
29384C108
13F reference period
Q2 2026
13F holders
127
13D/G owners
7
CIK / CUSIP context first
Open Q2 2026 holders
TRDA full holder history
Entrada Therapeutics, Inc. SEC filings
Entrada Therapeutics, Inc. company facts
Entrada Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29384C108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
TRDA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| 5AM Ventures V, L.P. | 11% | $25,485,387 | 4,123,849 | Kush Parmar | 14 Nov 2025 | |||
| MPM BioVentures 2014, L.P. | 9.9% | $28,205,935 | 3,885,115 | ANSBERT GADICKE | 08 Sep 2026 | |||
| ROCHE FINANCE LTD | 6.9% | $23,019,270 | 2,569,115 | Roche Finance Ltd | 31 Dec 2024 | |||
| BlackRock, Inc. | 5.3% | $17,691,090 | 1,974,452 | BlackRock, Inc. | 31 Dec 2024 | |||
| JANUS HENDERSON GROUP PLC | 4% | -27% | $9,964,391 | -$3,932,443 | 1,521,281 | -28% | JANUS HENDERSON GROUP PLC | 30 Jun 2025 |
| TCG Crossover GP I, LLC | 2.7% | -46% | $7,803,293 | -$6,308,359 | 1,060,230 | -45% | TCG Crossover GP I, LLC | 30 Jun 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.9% | -84% | $2,091,051 | -$12,800,322 | 360,526 | -86% | T. Rowe Price Associates, Inc. | 30 Sep 2025 |
As of 30 Jun 2026,
127
institutional investors reported holding
shares of
Entrada Therapeutics, Inc. - Common Stock (TRDA).
This represents
74%
of the company’s total
outstanding shares.
29.05M
Full value: 29,052,007 · shares · 30 Jun 202639.24M
Full value: 39,243,586 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
65%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 13% | 5,072,730 | 0% | 0.19% | $37,335,293 |
| 5AM Venture Management, LLC | 10% | 4,056,379 | 0% | 10% | $29,854,949 |
| BlackRock, Inc. | 6.6% | 2,583,333 | +9.5% | 0% | $19,013,332 |
| Merck & Co., Inc. | 4.4% | 1,739,768 | 2.4% | $12,804,692 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 1,269,634 | +1.1% | 0% | $9,344,506 |
| MPM BIOIMPACT LLC | 3.2% | 1,253,053 | 0.56% | $9,222,470 | |
| TCG Crossover Management, LLC | 2.7% | 1,060,230 | -54% | 0.19% | $7,803,293 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.4% | 954,419 | -7.8% | 0% | $7,024,524 |
| MILLENNIUM MANAGEMENT LLC | 1.9% | 763,959 | +47% | 0% | $5,622,738 |
| StepStone Group LP | 1.9% | 761,277 | 0% | 0.26% | $5,602,999 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 717,430 | +7.5% | 0% | $5,281,368 |
| AQR CAPITAL MANAGEMENT LLC | 1.8% | 699,537 | +780% | 0% | $5,148,591 |
| STATE STREET CORP | 1.5% | 596,677 | +12% | 0% | $4,391,543 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.4% | 542,316 | +3.1% | 0% | $3,992,000 |
| JPMORGAN CHASE & CO | 1.3% | 496,457 | +3244% | 0% | $3,827,683 |
| ACADIAN ASSET MANAGEMENT LLC | 1% | 400,862 | +20% | 0% | $2,945,000 |
| CITADEL ADVISORS LLC | 1% | 394,323 | +83% | 0% | $2,902,217 |
| DIMENSIONAL FUND ADVISORS LP | 0.96% | 376,136 | +16% | 0% | $2,769,577 |
| NORTHERN TRUST CORP | 0.79% | 309,942 | +32% | 0% | $2,281,173 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.77% | 303,459 | -9.1% | 0.01% | $2,233,458 |
| Nantahala Capital Management, LLC | 0.77% | 300,575 | +89% | 0.13% | $2,212,232 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.65% | 254,130 | +15% | 0% | $1,870,397 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.5% | 197,136 | -8.2% | 0% | $1,450,921 |
| Longaeva Partners L.P. | 0.5% | 195,237 | -4.8% | 0.04% | $1,436,944 |
| MORGAN STANLEY | 0.49% | 191,650 | +8.8% | 0% | $1,410,544 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
20
Headline period
Q2 2026
Rows shown
1-20 of 20
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 112,620 | $698,136 | -$114,522 | $6.35 | 20 |
| 2026 Q2 | 29,052,007 | $213,997,599 | +$23,782,839 | $7.36 | 127 |
| 2026 Q1 | 25,477,255 | $321,439,067 | +$9,380,200 | $12.62 | 118 |
| 2025 Q4 | 24,428,116 | $250,955,377 | +$6,143,063 | $10.28 | 113 |
| 2025 Q3 | 28,408,651 | $164,766,270 | -$9,410,304 | $5.80 | 114 |
| 2025 Q2 | 29,583,750 | $198,790,015 | -$4,881,409 | $6.72 | 105 |
| 2025 Q1 | 30,241,830 | $274,509,238 | -$4,478,805 | $9.04 | 110 |
| 2024 Q4 | 30,637,008 | $529,755,566 | +$9,629,460 | $17.29 | 102 |
| 2024 Q3 | 30,099,996 | $481,057,545 | +$6,089,620 | $15.98 | 97 |
| 2024 Q2 | 29,668,185 | $422,803,373 | +$52,052,901 | $14.25 | 82 |
| 2024 Q1 | 26,027,444 | $368,797,900 | -$3,772,264 | $14.17 | 76 |
| 2023 Q4 | 26,281,861 | $396,641,035 | +$3,492,844 | $15.09 | 62 |
| 2023 Q3 | 26,035,608 | $411,375,608 | +$4,515,692 | $15.80 | 55 |
| 2023 Q2 | 25,751,810 | $389,877,766 | +$13,317,282 | $15.14 | 56 |
| 2023 Q1 | 24,900,040 | $361,043,649 | +$2,708,627 | $14.50 | 53 |
| 2022 Q4 | 24,715,588 | $334,178,958 | +$2,434,963 | $13.52 | 46 |
| 2022 Q3 | 24,517,008 | $386,369,092 | -$2,728,204 | $15.76 | 33 |
| 2022 Q2 | 24,778,477 | $301,833,417 | -$12,927,920 | $12.18 | 35 |
| 2022 Q1 | 25,876,494 | $242,821,140 | +$2,263,033 | $9.39 | 48 |
| 2021 Q4 | 24,861,440 | $425,110,000 | +$413,748,000 | $17.12 | 45 |